OUTSET MEDICAL INC -,001

Outset Medical received FDA clearance for its next-generation Tablo platform, highlighting enhanced cybersecurity, reliability and an upgrade path for existing customers. Full-year 2025 revenue was $119.5 million, up 5% year-over-year, with non-GAAP gross margin expanding to 39.6% (41.1% ex-manufacturing under-absorption) and continued reduction in operating loss and cash burn. The company ended Q4 with $173 million in cash and guided 2026 revenue of $125–130 million, low- to mid-40% non-GAAP gross margin, and lower full-year cash use than 2025 as it advances toward profitability. » More on finance.yahoo.com

Outset Medical named Derick Elliott effective immediately as executive vice president of commercial; he will lead the sales organizations for acute care, post-acute care and home care and report to CEO Leslie Trigg. Elliott brings more than 30 years of sales experience from Stryker, Cardinal Health and most recently SpendMend. The San Jose–based company sells the FDA-approved Tablo hemodialysis system, used in more than 1,000 U.S. facilities; most recently revenue was $119.48 million. The stock trades at $4.08 (market capitalization $74.53 million), gained 11% last week but is down notably over six months; analysts view the stock as undervalued, according to InvestingPro. » More on de.investing.com

Outset Medical reported Q4 revenue of $28.9 million, a 2% decline year-over-year, and full-year revenue of $119.5 million, up 5%. Gross margin rose to 42.4% in the quarter and full-year margin improved to 39.1%; year-end cash was $173 million and adjusted net loss narrowed to $15.1 million. Management guided 2026 revenue of $125–130 million and a non-GAAP gross margin in the low-to-mid-40% range and plans a second-quarter launch of its next-generation Tablo platform. TD Cowen and BTIG cut price targets but maintained Buy ratings, citing a stable sales force, an expanding deal pipeline, recurring revenue and improving margins. » More on finance.yahoo.com